PHGE insider transaction filings
BiomX Inc. — 25 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-03-18. Screen PHGE transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-18 | 4 | Yeganeh Reuven — Director, 10% owner | Conversion (C): 450,000 @ $2 · Sale (S): 450,000 @ $5 · Conversion (C): 530,000 @ $2 · Sale (S): 530,000 @ $5 · Conversion (C): 900 (derivative) @ $0 · Conversion (C): 1,060 (derivative) @ $0 · +3 more | EDGAR |
| 2026-03-13 | 4 | Yeganeh Reuven — Director, 10% owner | Conversion (C): 300,000 @ $2 · Sale (S): 300,000 @ $5 · Conversion (C): 370,000 @ $2 · Sale (S): 370,000 @ $5 · Conversion (C): 600 (derivative) @ $0 · Conversion (C): 740 (derivative) @ $0 | EDGAR |
| 2025-04-23 | 4 | Flynn James E — Director DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director Deerfield Mgmt V, L.P. — Director Deerfield Mgmt HIF, L.P. — Director Deerfield Private Design Fund V, L.P. — Director Deerfield Healthcare Innovations Fund II, L.P. — Director | Grant/award (A): 1,611,864 (derivative) · Grant/award (A): 1,611,864 (derivative) | EDGAR |
| 2025-04-21 | 4/A | Merril Gregory Louis — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Bassan Merav — Chief Development Officer | Grant/award (A): 79,597 @ $0 · Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Solomon Jonathan Eitan — Chief Executive Officer, Director | Grant/award (A): 126,748 @ $0 · Grant/award (A): 380,500 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | GOODMAN JESSE — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Moses Alan Charles — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Blum Susan — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Greig Russell — Director | Grant/award (A): 35,200 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Wolfson Marina — Chief Financial Officer | Grant/award (A): 68,545 @ $0 · Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | Williams Eddie — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4/A | LEFF JONATHAN S — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Wolfson Marina — Chief Financial Officer | Grant/award (A): 68,545 @ $0 · Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Greig Russell — Director | Grant/award (A): 35,200 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | GOODMAN JESSE — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Bassan Merav — Chief Development Officer | Grant/award (A): 79,597 @ $0 · Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Moses Alan Charles — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Solomon Jonathan Eitan — Chief Executive Officer, Director | Grant/award (A): 126,748 @ $0 · Grant/award (A): 380,500 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Blum Susan — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Williams Eddie — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | LEFF JONATHAN S — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Flynn James E — Director DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Cystic Fibrosis Foundation — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2025-03-03 | 4 | Flynn James E — Director DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) — Director Deerfield Mgmt V, L.P. — Director Deerfield Mgmt HIF, L.P. — Director Deerfield Private Design Fund V, L.P. — Director Deerfield Healthcare Innovations Fund II, L.P. — Director | Option exercise (M): 353,249 @ $0.93 · Option exercise (M): 353,249 @ $0.93 · Option exercise (M): 1,611,863 (derivative) · Option exercise (M): 1,611,863 (derivative) · Grant/award (A): 1,258,614 (derivative) · Grant/award (A): 1,258,614 (derivative) | EDGAR |
Recent 8-K events — BiomX Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PHGE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →